BIBLIOGRAPHY
[1] Strauss SJ, Frezza AM, Abecassis N et al; ESMO Guidelines
Committee, EURACAN, GENTURIS and ERN PaedCan. Electronic address:
clinicalguidelines@esmo.org. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN
PaedCan Clinical Practice Guideline for diagnosis, treatment and
follow-up. Ann Oncol. 2021 Dec;32(12):1520-1536. Doi:
10.1016/j.annonc.2021.08.1995. Epub 2021 Sep 6. PMID: 34500044.
[2] Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification
of Soft Tissue Tumors: news and perspectives. Pathologica. 2021
Apr;113(2):70-84. Doi: 10.32074/1591-951X-213. Epub 2020 Nov 3. PMID:
33179614; PMCID: PMC8167394.
[3] Newman EN, Jones RL, Hawkins DS. An evaluation of
[F-18]-fluorodeoxy-D-glucose positron emission tomography, bone
scan, and bone marrow aspiration/biopsy as staging investigations in
Ewing sarcoma. Pediatr Blood Cancer. 2013;60(7):1113-1117
[4] Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors
in Ewing’s tumor of bone: analysis of 975 patients from the European
Inter- group Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol.
2000;18(17):3108-3114.
[5] Thiel U, Wawer A, von Luettichau I, Bender HU, Blaeschke F,
Grunewald TG, Steinborn M, Röper B, Bonig H, Klingebiel T, Bader P,
Koscielniak E, Paulussen M, Dirksen U, Juergens H, Kolb HJ, Burdach SE.
Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma
patients with fatal outcome irrespective of therapy in contrast to
curable patients with multiple bone metastases but unaffected marrow.
Oncotarget. 2016 Oct 25;7(43):70959-70968. doi:
10.18632/oncotarget.10938. PMID: 27486822; PMCID: PMC5342601.
[6]
Martin
McCabe,
Laura
Kirton,
Maria
Khan,
Nicola
Fenwick,
Sandra
J. Strauss,
Claudia
Valverde,
Cristina
Mata,
Nathalie
Gaspar,
Roberto
Luksch,
Alessandra
Longhi,
Uta
Dirksen,
Marianne
Phillips,
Akmal
Safwat,
Hans
Gelderblom,
Thomas
Kuehne,
Jukka
Kanerva,
Andrew
J. Westwood,
Stefano
Ferrari,
Jeremy
Whelan, and
Keith
Wheatley. Phase III assessment of topotecan and cyclophosphamide and
high-dose ifosfamide in rEECur: An international randomized controlled
trial of chemotherapy for the treatment of recurrent and primary
refractory Ewing sarcoma (RR-ES). Journal of Clinical Oncology,
Volume 40, Number
17_suppl.doi.org/10.1200/JCO.2022.40.17_suppl.LB
[7] National Institutes of Health NCI. Common Terminology Criteria
for Adverse Events (CTCAE) Version 5.0. In: U.S: Department of Health
and Human Services, 2017
[8] Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L. Anemia and
thrombocytopenia in patients undergoing chemotherapy for solid tumors: a
descriptive study of a large outpatient oncology practice database,
2000-2007. Clin Ther. 2009;31 Pt 2:2416-32. Doi:
10.1016/j.clinthera.2009.11.020. PMID: 20110050.
[9] Hitron A, Steinke D, Sutphin S, Lawson A, Talbert J, Adams V.
Incidence and risk factors of clinically significant
chemotherapy-induced thrombocytopenia in patients with solid tumors.
Journal of Oncology Pharmacy Practice. 2011;17(4):312-319.
Doi:10.1177/1078155210380293
[10] Peter Mauch; Louis Constine; Joel Greenberger; William Knospe;
Jessie Sullivan; Jane L. Liesveld; H.Joachim Deeg (1995). Hematopoietic
stem cell compartment: Acute and late effects of radiation therapy and
chemotherapy. , 31(5), 1319–1339. Doi:10.1016/0360-3016(94)00430-s
[11] Fornari, Chiara; Oplustil O’Connor, Lenka; Pin, Carmen; Smith,
Aaron; Yates, James W.T.; Cheung, S.Y. Amy; Jodrell, Duncan I.;
Mettetal, Jerome T.; Collins, Teresa A. (2019). Quantifying Drug‐Induced
Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology
Model. CPT: Pharmacometrics & Systems Pharmacology, (), psp4.12459–.
doi:10.1002/psp4.12459
[12] Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J,
Liesveld JL, Deeg HJ. Hematopoietic stem cell compartment: acute and
late effects of radiation therapy and chemotherapy. Int J Radiat Oncol
Biol Phys. 1995 Mar 30;31(5):1319-39. Doi: 10.1016/0360-3016(94)00430-S.
PMID: 7713791.
[13] Shao L, Wang Y, Chang J, Luo Y, Meng A, Zhou D. Hematopoietic
stem cell senescence and cancer therapy-induced long-term bone marrow
injury. Transl Cancer Res. 2013 Oct;2(5):397-411. Doi:
10.3978/j.issn.2218-676X.2013.07.03. PMID: 24605290; PMCID: PMC3941916.
[14] Rafieemehr H, Maleki Behzad M, Azandeh S, Farshchi N, Ghasemi
Dehcheshmeh M, Saki N. Chemo/radiotherapy-Induced Bone Marrow Niche
Alterations. Cancer Invest. 2021 Feb;39(2):180-194. Doi:
10.1080/07357907.2020.1855353. Epub 2020 Dec 10. PMID: 33225760.
[15] Shaw JL, Nielson CM, Park JK, Marongiu A, Soff GA. The
incidence of thrombocytopenia in adult patients receiving chemotherapy
for solid tumors or hematologic malignancies. Eur J Haematol. 2021
May;106(5):662-672. Doi: 10.1111/ejh.13595. Epub 2021 Feb 16. PMID:
33544940; PMCID: PMC8248430.
[16] Ten Berg MJ, et al. Thrombocytopenia in adult cancer patients
receiving cytotoxic chemotherapy: results from a retrospective hospital-
based cohort study. Drug Saf. 2011;34(12):1151–60.
https://doi.org/10.2165/11594310-000000000-00000
[17] Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA,
Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue
sarcomas: results of phase II and pilot studies—dose-response and
schedule dependence. J Clin Oncol. 1997 Jun;15(6):2378-84. Doi:
10.1200/JCO.1997.15.6.2378. PMID: 9196153.
[18] Merjaneh N, Young J, Mangoli A, Olsen M, Setty B, Lane A,
Nagarajan R, Pressey JG, Turpin B. Chemotherapy-induced thrombocytopenia
in Ewing sarcoma: Implications and potential for romiplostim supportive
care. Pediatr Blood Cancer. 2022 Jul;69(7):e29548. Doi:
10.1002/pbc.29548. Epub 2021 Dec 28. PMID: 34962714.
[19] Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S,
Laiho E, Kanesan K, Cantor SB, Benjamin RS. Incidence, cost, and
outcomes of bleeding and chemotherapy dose modification among solid
tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol.
2001 Feb 15;19(4):1137-46. Doi: 10.1200/JCO.2001.19.4.1137. PMID:
11181679.
[20] DA Silva, Levy C, Allouache D, Hrab I, Morel A, Faveyrial A,
Gunzer K, Johnson A, Segura C, Licaj I, Damaj G, Emile G. Efficacy and
Safety of Weekly Paclitaxel in Breast Cancer With Symptomatic Bone
Marrow Infiltration. Anticancer Res. 2020. May;40(5):2955-2960. doi:
10.21873/anticanres.14274. PMID: 32366448
[21] Pahouja G, Wesolowski R, Reinbolt R, Tozbikian G, Berger M,
Mangini N, Lustberg MB. Stabilization of bone marrow infiltration by
metastatic breast cancer with continuous doxorubicin. Cancer Treat
Commun. 2015;3:28-32. doi: 10.1016/j.ctrc.2014.11.002. PMID: 25914871;
PMCID: PMC4408922.
[22] Chan B, Lee JS, Yuan Y. Case report: An exceptional responder
of low-dose continuous 5-FU in a patient with de-novo stage IV
triple-negative breast cancer with liver and bone marrow failure. Front
Oncol. 2024 Jan 15;13:1305584. doi: 10.3389/fonc.2023.1305584. PMID:
38288100; PMCID: PMC10823013.
[23] Milrod CJ, Binney G, Khan MA. Pancytopenia associated with bone
marrow infiltration from late relapse of neuroblastoma. Lancet Oncol.
2023 Dec;24(12):e519. doi: 10.1016/S1470-2045(23)00520-X. PMID:
38040004.
[24] Khan SJ, Ishaq I, Saeed H, Fayyaz MB, Baqari SAS, Wali RM. Bone
Marrow Involvement in Metastatic Pediatric Ewing Sarcoma. J Coll
Physicians Surg Pak. 2017 Aug;27(8):502-504. PMID: 28903844.
[25] Krsková L, Mrhalová M, Hilská I, Sumerauer D, Drahokoupilová E,
Múdry P, Kodet R. Detection and clinical significance of bone marrow
involvement in patients with rhabdomyosarcoma. Virchows Arch. 2010
May;456(5):463-72. doi: 10.1007/s00428-010-0913-9. Epub 2010 Apr 20.
PMID: 20405298.
[26] Germans SK, Weinberg OK. Metastatic angiosarcoma in a bone
marrow biopsy. Blood. 2022 Nov 3;140(18):2001. doi:
10.1182/blood.2022018036. PMID: 36326791.
[27] Rosenberg AE, Garber JE, Bennett W, Bhan AK, Antman KH, Mark
EJ. Epithelioid sarcoma with diffuse bone marrow metastases and
associated leukemoid reaction. A case report and brief literature
review. Am J Clin Pathol. 1988 Dec;90(6):723-6. doi:
10.1093/ajcp/90.6.723. PMID: 3057863.
[28] Jiang L, Admirand JH, Moran C, Ford RJ, Bueso-Ramos CE.
Mediastinal follicular dendritic cell sarcoma involving bone marrow: a
case report and review of the literature. Ann Diagn Pathol. 2006
Dec;10(6):357-62. doi: 10.1016/j.anndiagpath.2005.11.005. PMID:
17126255.
[29] Cheng JJ, Mott RT, Savage PD, Paluri RK. Metastatic Alveolar
Rhabdomyosarcoma with Extensive Bone Marrow Replacement in an Older
Adult. Case Rep Oncol. 2021 Oct 21;14(3):1505-1510. doi:
10.1159/000519595. PMID: 34899243; PMCID: PMC8613543.
[30] Aida Y, Ueki T, Kirihara T, Takeda W, Kurihara T, Sato K,
Shimizu I, Hiroshima Y, Sumi M, Ueno M, Ichikawa N, Watanabe M,
Kobayashi H. Bone marrow metastasis of rhabdomyosarcoma mimicking acute
leukemia: a case report and review of the literature. Intern Med.
2015;54(6):643-50. doi: 10.2169/internalmedicine.54.2473. Epub 2015 Jan
15. PMID: 25786457.